Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419757 · ClinicalTrials.gov registry record · Phase 3
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
- 20
- Study locations
NCT00419757: Completed Phase 3 study of Asthma, sponsored by AstraZeneca.
NCT00419757 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 558 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00419757, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
Primary Outcome
Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks, with baseline value as covariate.
Conditions Studied
Interventions
- DRUG Budesonide/formoterol (SYMBICORT) pMDI
- DRUG Budesonide HFA pMDI
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Chula Vista
- Research Site - Fresno
- Research Site - Fullerton
- Research Site - Los Angeles
- Research Site - National City
- Research Site - Rancho Cordova
- Research Site - Rancho Mirage
- Research Site - Riverside
- Research Site - Sacramento
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - Stockton
- Research Site - Torrance
Florida
- Research Site - Largo
- Research Site - Miami
- Research Site - Naranja
- Research Site - North Miami
- Research Site - Orlando
Colorado
- Research Site - Pueblo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00419757 record still lists
NCT00419757 is an interventional study that assigns participants to a tested intervention. The registered 558 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Budesonide/formoterol (SYMBICORT) pMDI is the first listed.
NCT00419757 names 20 study sites across 3 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00419757 about?
NCT00419757 is a clinical study titled "An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma". The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
What is the current status of trial NCT00419757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2007-01. Estimated completion is 2008-06.
What conditions does trial NCT00419757 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00419757?
The interventions under investigation include: Budesonide/formoterol (SYMBICORT) pMDI (DRUG), Budesonide HFA pMDI (DRUG).
Who is sponsoring clinical trial NCT00419757?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00419757 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00419757's enrollment target sits among peer trials
558 73rd of 374 higher than 302 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07173751 · 558 participants · Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia